Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Cantor Fitzgerald initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, July 24th. They issued an “overweight” rating and a $11.00 price target for the company. Finally, Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eupraxia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Eupraxia Pharmaceuticals Stock Up 3.5%

Shares of Eupraxia Pharmaceuticals stock opened at $6.56 on Friday. The stock’s fifty day moving average is $5.79 and its two-hundred day moving average is $5.11. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $7.19. The company has a market capitalization of $235.90 million, a PE ratio of -7.54 and a beta of 1.47.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. As a group, research analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Quadrature Capital Ltd purchased a new stake in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth $61,000. TCI Wealth Advisors Inc. purchased a new position in Eupraxia Pharmaceuticals in the third quarter valued at about $65,000. Bank of America Corp DE raised its holdings in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after buying an additional 16,017 shares during the last quarter. Finally, Guardian Partners Inc. bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at about $147,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.